(OAKVILLE, Ontario) le 7 juin 2022 – FORUS Therapeutics Inc. (« FORUS »), a le plaisir d’annoncer que le 31 mai 2022, Santé Canada a autorisé la vente de XPOVIO® (selinexor) en association avec le bortézomib et la dexaméthasone pour le traitement des patients...
(Saint-lgnace-de-Stanbridge, Quebec) May 28th, 2022 – FORUS was a proud sponsor and participant in the Défi Cyclo-Myélome. This is the 10th year of this important event which aims to increase awareness about multiple myeloma and raise funds for the Myeloma Canada...
(TORONTO, Ontario) May 2-3, 2022 – FORUS Therapeutics Inc, a Canadian Life Sciences company specialized in developing and commercializing unique and differentiated oncology focused therapies is proud to be participating and presenting at the 2022 Bloom Burton &...
(OAKVILLE, Ontario) February 22, 2022 – FORUS Therapeutics, a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer, today announced it has secured $2.5M CAD in growth capital...
FORUS Therapeutics a le plaisir d’annoncer la nomination de Marie-Josèphe Champagne au poste de liaison médicale scientifiques principale pour le Québec et l’Atlantique. Marie-Josèphe a plus de 18 ans d’expérience dans l’industrie pharmaceutique dans des rôles...
Despite all the global and local challenges; related and unrelated to the pandemic, 2021 has been a year of tremendous growth, progress and development at FORUS. We are excited about 2022 and look forward to fulfilling our mission by bringing innovative new medicines...
Recent Comments